Slingshot members are tracking this event:

Initiation of the Iomab-B's pivotal Phase 3 trial in AML refractory/relapsing patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks




Additional Information

Management Comment Iomab-B works by ablating the patient’s bone marrow and leukemia thus paving the way for a transplant. We licensed Iomab-B from the Fred Hutchinson Cancer Research Center, which is widely considered the “temple” of transplant and it has been studied in over 250 patients to date. Our upcoming pivotal trial will enroll 150 patients and is expected to read out top line results in the second half of 2018.
Additional Relevant Details The company's most advance therapy is Iomab-B, which is the subject of a pivotal Phase 3 trial initiated in June to evaluate its efficacy as an induction and conditioning agent used to prepare patients 55 and older with relapsed or refractory AML for a hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT). 
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Iomab-b